Guava leaf extracts alleviate fatty liver via expression of adiponectin receptors in SHRSP.Z-Leprfa/Izm rats

Nutrition & Metabolism

Ming Gao¹  Tonghua Liu³  Xiangyu Guo²  Hisae Yoshitomi⁴ 

[1] 11-68 Koshien Kyuban-cho, Nishinomiya 663-8179, Japan;Beijing University of Chinese Medicine subsidiary Dongfang Hospital, Beijing, China;Beijing University of Chinese Medicine, Beijing, China;School of Pharmaceutical Sciences, Mukogawa Women's University, Nishinomiya, Japan

关键词: SHRSP.Z-Leprfa/IzmDmcr rat;    Guava leaf extract;    Adiponectin;    Fatty liver;   

Others  :  820071
DOI  :  10.1186/1743-7075-9-13

 received in 2011-12-24, accepted in 2012-02-20,  发布年份 2012

【 摘 要 】

Background

In recent years, the number of people with metabolic syndrome has continued to rise because of changing eating habits, and accompanying hepatic steatosis patients have also increased. This study examined the effect of guava leaf extract on liver fat accumulation using SHRSP.Z-Leprfa/IzmDmcr rats (SHRSP/ZF), which are a metabolic syndrome model animal.

Method

Seven-week-old male SHRSP/ZF rats were divided into two groups, a control group and a guava leaf extract (GLE) group. We gave 2 g/kg/day GLE or water by forced administration for 6 weeks. After the experimental period, the rats were sacrificed and organ weight, hepatic lipids, serum aminotransferase and liver pathology were examined. To search for a possible mechanism, we examined the changes of key enzyme and transcriptional factors involved in hepatic fatty acid beta-oxidation.

Results

The triglyceride content of the liver significantly decreased in the GLE group in comparison with the control group, and decreased fat-drop formation in the liver tissue graft in the GLE group was observed. In addition, the improvement of liver organization impairments with fat accumulation restriction was suggested because blood AST and ALT in the GLE group significantly decreased. Furthermore, it was supposed that the activity of AMPK and PPARα significantly increased in the GLE group via the increase of adiponectin receptors. These were thought to be associated with the decrease of the triglyceride content in the liver because AMPK and PPARα in liver tissue control energy metabolism or lipid composition. On the other hand, insulin resistance was suggested to have improved by the fatty liver improvement in GLE.

Conclusion

Our results indicate that administration of GLE may have preventive effects of hepatic accumulation and ameliorated hepatic insulin resistance by enhancing the adiponectin beta-oxidation system. Guava leaf may be potentially useful for hepatic steatosis without the side effects of long-term treatments.

【 授权许可】

   
2012 Yoshitomi et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Kamei N, Tobe K, Suzuki R, Ohsugi M, Watanabe T, Kubota N, Ohtsuka-Kowatari N, Kumagai K, Sakamoto K, Kobayashi M, Yamauchi T, Ueki K, Oishi Y, Nishimura S, Manabe I, Hashimoto H, Ohnishi Y, Ogata H, Tokuyama K, Tsunoda M, Ide T, Murakami K, Nagai R, Kadowaki T: Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 2006, 281:26602-26614.
• [2]Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N: Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50:1844-1850.
• [3]Clark JM, Brancati FL, Diehl AM: The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003, 98:960-967.
• [4]Gutierrez RM, Mitchell S, Solis RV: Psidium guajava: a review of its traditional uses, phytochemistry and pharmacology. J Ethnopharmacol 2008, 117:1-27.
• [5]Keji C: Understanding and treatment of diabetes mellitus by traditional Chinese medicine. Am J Chin Med 1981, 9:93-94.
• [6]Begum S, Hassan SI, Siddiqui BS: Two new triterpenoids from the fresh leaves of Psidium guajava. Planta Med 2002, 68:1149-1152.
• [7]Begum S, Hassan SI, Ali SN, Siddiqui BS: Chemical constituents from the leaves of Psidium guajava. Nat Prod Res 2004, 18:135-140.
• [8]Lozoya X, Meckes M, Abou-Zaid M, Tortoriello J, Nozzolillo C, Arnason JT: Quercetin glycosides in Psidium guajava L. leaves and determination of a spasmolytic principle. Arch Med Res 1994, 25:11-15.
• [9]de Rezende FM, Furlan CM: Anthocyanins and tannins in ozone-fumigated guava trees. Chemosphere 2009, 76:1445-1450.
• [10]Oh WK, Lee CH, Lee MS, Bae EY, Sohn CB, Oh H, Kim BY, Ahn JS: Antidiabetic effects of extracts from Psidium guajava. J Ethnopharmacol 2005, 96:411-415.
• [11]Deguchi Y, Miyazaki K: Anti-hyperglycemic and anti-hyperlipidemic effects of guava leaf extract. Nutr Metab 2010, 7:9. BioMed Central Full Text
• [12]Shen SC, Cheng FC, Wu NJ: Effect of guava (Psidium guajava Linn.) leaf soluble solids on glucose metabolism in type 2 diabetic rats. Phytother Res 2008, 22:1458-1464.
• [13]Hiraoka-Yamamoto J, Nara Y, Yasui N, Onobayashi Y, Tsuchikura S, Ikeda K: Establishment of a new animal model of metabolic syndrome: SHRSP fatty (fa/fa) rats. Clin Exp Pharmacol Physiol 2004, 31:107-109.
• [14]Ueno T, Takagi H, Fukuda N, Takahashi A, Yao EH, Mitsumata M, Hiraoka-Yamamoto J, Ikeda K, Matsumoto K, Yamori Y: Cardiovascular remodeling and metabolic abnormalities in SHRSP.Z-Lepr(fa)/IzmDmcr rats as a new model of metabolic syndrome. Hypertens Res 2008, 31:1021-1031.
• [15]Folch J, Lees M, Sloane Stanley GH: A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957, 226:497-509.
• [16]Ikeda I, Cha JY, Yanagita T, Nakatani N, Oogami K, Imaizumi K, Yazawa K: Effects of dietary alpha-linolenic, eicosapentaenoic and docosahexaenoic acids on hepatic lipogenesis and beta-oxidation in rats. Biosci Biotechnol Biochem 1998, 62:675-680.
• [17]Ueno T, Fukuda N, Nagase H, Tsunemi A, Tahira K, Matsumoto T, Hiraoka-Yamamoto J, Ikeda K, Mitsumata M, Sato Y, Soma M, Matsumoto K, Yamori Y: Atherogenic dyslipidemia and altered hepatic gene expression in SHRSP.Z-Leprfa/IzmDmcr rats. Int J Mol Med 2009, 23:313-320.
• [18]Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB Jr, Haffner SM: Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 2005, 54:3140-3147.
• [19]Kadowaki T: Insights into insulin resistance and type 2 diabetes from knockout mouse models. J Clin Invest 2000, 106:459-465.
• [20]Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, Yazaki Y, Kadowaki T: Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998, 101:1354-1361.
• [21]Fève B, Bastard JP: The role of interleukins in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 2009, 5(6):305-311.
• [22]Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001, 7:941-946.
• [23]Kadowaki T, Yamauchi T: Adiponectin and adiponectin receptors. Endocr Rev 2005, 26:439-451.
• [24]Tsuchida A, Yamauchi T, Ito Y, Hada Y, Maki T, Takekawa S, Kamon J, Kobayashi M, Suzuki R, Hara K, Kubota N, Terauchi Y, Froguel P, Nakae J, Kasuga M, Accili D, Tobe K, Ueki K, Nagai R, Kadowaki T: Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem 2004, 279:30817-30822.
• [25]Rao MS, Reddy JK: Peroxisomal beta-oxidation and steatohepatitis. Semin Liver Dis 2001, 21:43-55.
• [26]Reddy JK, Hashimoto T: Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu Rev Nutr 2001, 21:193-230.
• [27]Steinberg GR, Macaulay SL, Febbraio MA, Kemp BE: AMP-activated protein kinase-the fat controller of the energy railroad. Can J Physiol Pharmacol 2006, 84:655-665.
• [28]Towler MC, Hardie DG: AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 2007, 100:328-341.
• [29]Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
• [30]Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, Okada-Iwabu M, Kawamoto S, Kubota N, Kubota T, Ito Y, Kamon J, Tsuchida A, Kumagai K, Kozono H, Hada Y, Ogata H, Tokuyama K, Tsunoda M, Ide T, Murakami K, Awazawa M, Takamoto I, Froguel P, Hara K, Tobe K, Nagai R, Ueki K, Kadowaki T: Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007, 13:332-339.
• [31]Kim MJ, Maachi M, Debard C, Loizon E, Clement K, Bruckert E, Hainque B, Capeau J, Vidal H, Bastard JP: Increased adiponectin receptor-1 expression in adipose tissue of impaired glucose-tolerant obese subjects during weight loss. Eur J Endocrinol 2006, 155:161-165.
• [32]Rasmussen MS, Lihn AS, Pedersen SB, Bruun JM, Rasmussen M, Richelsen B: Adiponectin receptors in human adipose tissue: effects of obesity, weight loss, and fat depots. Obesity (Silver Spring) 2006, 14:28-35.
• [33]Bluher M, Bullen JW Jr, Lee JH, Kralisch S, Fasshauer M, Kloting N, Niebauer J, Schon MR, Williams CJ, Mantzoros CS: Circulating adiponectin and expression of adiponectin receptors in human skeletal muscle: associations with metabolic parameters and insulin resistance and regulation by physical training. J Clin Endocrinol Metab 2006, 91:2310-2316.
• [34]Neumeier M, Weigert J, Schaffler A, Weiss T, Kirchner S, Laberer S, Scholmerich J, Buechler C: Regulation of adiponectin receptor 1 in human hepatocytes by agonists of nuclear receptors. Biochem Biophys Res Commun 2005, 334:924-929.
• [35]Sun X, Han R, Wang Z, Chen Y: Regulation of adiponectin receptors in hepatocytes by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Diabetologia 2006, 49:1303-1310.